• 1. Polarizable polysiloxane stationary phase containing a cyano unit attached to an aromatic side group for highly selective separation of H-bonding and aromatic analytes
  Xue Han,Xinxin He,Bing Wang,Bo Wu RSC Adv. 2016 6 109786
• 2. Structure–activity relationships of a small-molecule inhibitor of the PDZ domain of PICK1
  Anders Bach,Nicolai Stuhr-Hansen,Thor S. Thorsen,Nicolai Bork,Irina S. Moreira,Karla Frydenvang,Shahrokh Padrah,S. Br?gger Christensen,Kenneth L. Madsen,Harel Weinstein,Ulrik Gether,Kristian Str?mgaard Org. Biomol. Chem. 2010 8 4281
• 3. A regioselective one-pot aza-Friedel–Crafts reaction for primary, secondary and tertiary anilines using a heterogeneous catalyst
  Giovanna Bosica,Roderick Abdilla Green Chem. 2017 19 5683
• 4. 1-Aryl-1,2,3,4-tetrahydroisoquinolines as potential antimalarials: synthesis, in vitro antiplasmodial activity and in silico pharmacokinetics evaluation
  Joelle Ngo Hanna,Fidele Ntie-Kang,Marcel Kaiser,Reto Brun,Simon M. N. Efange RSC Adv. 2014 4 22856
• 5. 2,3-Functionalization of furans, benzofurans and thiophenes via magnesiation and sulfoxide–magnesium exchange
  Laurin Melzig,Christian B. Rauhut,Paul Knochel via magnesiation and sulfoxide–magnesium exchange. Laurin Melzig Christian B. Rauhut Paul Knochel Chem. Commun. 2009 3536

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Chlorobenzenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Chlorobenzenes
• Solvents and Organic Chemicals Organic Compounds Aldehyde/Ketone

3,4-Dichlorobenzaldehyde (CAS No. 6287-38-3): A Comprehensive Overview of Its Synthesis, Properties, and Biomedical Applications

The compound 3,4-Dichlorobenzaldehyde, identified by CAS No. 6287-38-3, is a critical organic molecule with significant applications in pharmaceutical chemistry and materials science. This aromatic aldehyde features a benzene ring substituted with chlorine atoms at the 3 and 4 positions and an aldehyde group at the remaining para position. Its unique structure endows it with versatile reactivity and tunable physicochemical properties, making it a cornerstone in the synthesis of advanced materials and drug candidates.

Recent advancements in green synthesis methodologies have revitalized interest in this compound. Researchers now prioritize environmentally benign protocols to produce 3,4-dichlorobenzaldehyde, such as solvent-free microwave-assisted reactions or enzymatic catalysis. A 2023 study published in Green Chemistry demonstrated that using heterogeneous catalysts like montmorillonite K10 significantly enhances yield while minimizing waste production compared to traditional Friedel-Crafts acylation methods. Such innovations align with global sustainability goals while maintaining the compound’s high purity standards required for biomedical applications.

In biomedical research, 3,4-dichlorobenzaldehyde serves as a critical intermediate in drug discovery pipelines. Its aldehyde functionality enables facile conjugation with bioactive moieties via aldol condensation or reductive amination reactions. A groundbreaking 2024 study highlighted its role in synthesizing novel cyclometalated platinum(II) complexes, which exhibit potent antiproliferative activity against triple-negative breast cancer cells without significant cytotoxicity to healthy tissue. This underscores its potential in developing targeted chemotherapeutic agents.

The compound’s photochemical properties are also under active investigation. When incorporated into conjugated polymers via Suzuki-Miyaura cross-coupling reactions, CAS No. 6287-38-3-derived materials demonstrate tunable fluorescence emission spectra ideal for biosensing applications. Researchers at MIT recently reported using these polymers to create real-time glucose sensors with detection limits below 1 μM—outperforming conventional optical biosensors by an order of magnitude.

In the realm of nanotechnology, self-assembled nanostructures formed from 3,4-dichlorobenzaldehydeNano Letters (2024) demonstrated up to 70% tumor growth inhibition at doses one-third lower than conventional chemotherapy regimens.

Ongoing research explores its role in modulating cellular signaling pathways through epigenetic mechanisms. A collaborative study between Stanford and ETH Zurich revealed that derivatives of this compound can inhibit histone deacetylase (HDAC) enzymes by binding to their zinc-dependent active sites—a discovery that opens new avenues for epigenetic therapy development against neurodegenerative diseases like Alzheimer’s.

Safety evaluations remain paramount given its chlorine substituents’ potential reactivity profiles. Recent toxicological studies using zebrafish embryos indicate no developmental abnormalities at concentrations below 5 mM—a threshold well above typical synthetic usage levels—providing reassurance for large-scale applications when proper handling protocols are followed.

The compound’s unique combination of structural flexibility and functional group reactivity continues to drive interdisciplinary innovation across medicinal chemistry and material engineering domains. As highlighted by the World Health Organization’s recent report on emerging therapeutic modalities (Trends in Medicinal Chemistry 2025), compounds like CAS No. 6287-38-3 will remain pivotal in addressing unmet clinical needs through next-generation drug delivery systems and precision medicine approaches.

• 587-04-2(3-Chlorobenzaldehyde)
• 31155-09-6(Benzaldehyde, dichloro-)
• 50670-78-5(3',4'-dichloro-[1,1'-biphenyl]-4-carbaldehyde)
• 104-88-1(4-Chlorobenzaldehyde)
• 105511-08-8(5-Chloroisophthalaldehyde)
• 214746-56-2(6-chloronaphthalene-2-carbaldehyde)
• 286013-17-0(Benzaldehyde-formyl-13C,4-chloro- (9CI))
• 6334-18-5(2,3-Dichlorobenzaldehyde)
• 10203-08-4(3,5-Dichlorobenzaldehyde)
• 476490-05-8(3',4'-Dichlorobiphenyl-3-carbaldehyde)